Viewing Study NCT06114004


Ignite Creation Date: 2025-12-24 @ 9:21 PM
Ignite Modification Date: 2026-02-25 @ 8:16 PM
Study NCT ID: NCT06114004
Status: RECRUITING
Last Update Posted: 2025-06-25
First Post: 2023-10-20
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
Sponsor: Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module